Anvifen - instructions for use, dose, side effects, contraindications

Excipients: for the dosage of 25 mg: giprolose - 1.3 mg, silicon dioxide colloid - 3.2 mg, lactose -109.1 mg, magnesium stearate -1.4 mg; for the dosage of 50 mg: giprolose - 1.3 mg, silicon dioxide colloid - 3.2 mg, lactose - 84.1 mg, magnesium stearate -1.4 mg; for the dosage of 125 mg: giprolose - 1.7 mg, silicon dioxide colloid - 4.0 mg, lactose - 42.5 mg, magnesium stearate - 1.8 mg; for the dosage of 250 mg: giprolose - 2.0 mg, silicon dioxide colloid - 8.0 mg, lactose - 86.5 mg, magnesium stearate - 3.5 mg.

Hard gelatin capsules contain: for dosage of 25 mg - water, gelatin, titanium dioxide (E 171); for a dosage of 50 mg - water, gelatin, dye azorubin (E 122),dye diamond blue (E 133), dye quinoline yellow (E 104), titanium dioxide (E 171); for the dosage of 125 mg - water, gelatin, dye azorubin (E 122), dye diamond blue (E 133), titanium dioxide (E 171); for a dosage of 250 mg - water, gelatin, dye azorubin (E 122), dye diamond blue (E 133), titanium dioxide (E 171).

Description:

Dosage of 25 mg - capsules of hard gelatinous white No. 3.

Dosage 50 mg - hard gelatin capsules No. 3, white body, lid blue.

Dosage of 125 mg - capsules of hard gelatin № 2, body of white color, cover of blue color.

Dosage of 250 mg - hard gelatin capsules № 0, body white, cover dark blue.

Contents of capsules - a mixture of powder and / or granules of white or white with a yellowish hue.

Pharmacotherapeutic group:Nootropic remedy

ATX: & nbsp

N.06.B Psychostimulants and nootropic drugs

Pharmacodynamics:

Nootropic agent, facilitates GABA-mediated transmission of nerve impulses in the central nervous system (direct effect on GABA-ergic receptors). The tranquilizing effect is combined with the activating effect.It also has antiplatelet, antioxidant and some anticonvulsant action.

Improves the functional state of the brain due to the normalization of its metabolism and influence on the cerebral blood flow (increases volumetric and linear speed, reduces vascular resistance, improves microcirculation, and has antiaggregant effect). It prolongs the latent period and shortens the duration and severity of nystagmus.

Does not affect cholino- and adrenergic receptors. Reduces vasovegetative symptoms (including headache, sensation of heaviness in the head, sleep disorders, irritability, emotional lability). At the course reception increases physical and mental efficiency (attention, memory, speed and accuracy of sensory-motor reactions).

Reduces the manifestation of asthenia (improves well-being, increases interest and initiative (motivation of activity)) without sedation or arousal. Helps reduce feelings of anxiety, tension and anxiety, normalizes sleep.

People of advanced age do not cause central nervous system depression, muscle-relaxing aftereffect is most often absent.

Pharmacokinetics:

Absorption is high, it penetrates well into all tissues of the body and across the blood-brain barrier (about 0.1% of the injected dose penetrates the brain tissue, and in young and elderly people in much more). Evenly distributed in the liver and kidneys. Metabolized in the liver - 80-95%, metabolites pharmacologically not active. Do not cumulate. After 3 hours begins to be excreted by the kidneys, while the concentration in the brain tissue does not decrease and is detected for another 6 hours. About 5% is excreted by the kidneys unchanged, partly with bile.

Indications:

Asthenic and anxiety-neurotic states.

Stammering, tics and enuresis in children.

Insomnia and nightly anxiety in the elderly.

Ménière's disease, dizziness associated with dysfunctions of the vestibular analyzer of various genesis; prevention of motion sickness with kinetosis.

As part of the complex therapy of alcohol withdrawal syndrome for the relief of psychopathological and somatovegetative disorders.

Contraindications:

Hypersensitivity, pregnancy, breastfeeding, children under 3 years.

Carefully:With erosive and ulcerative lesions of the gastrointestinal tract, hepatic insufficiency.

Pregnancy and lactation:Contraindicated.

Dosing and Administration:

Inside after eating 2-3-week courses. Adults and children from 14 years of 250-500 mg 3 times a day (maximum daily dose of 2500 mg). Children from 3 to 8 years of 50-100 mg 3 times a day; from 8 to 14 years - 250 mg 3 times a day. A single maximum dose in adults and children from the age of 14 is 750 mg, in people over 60 years - 500 mg, in children under 8 years - 150 mg, from 8 to 14 years - 250 mg.

Alcohol withdrawal: 250-500 mg 3 times a day and 750 mg at night, with a gradual decrease in the daily dose to normal for adults. Treatment of dizziness in dysfunctions of the vestibular apparatus and Ménière's disease: 250 mg 3 times a day for 14 days.

Prevention of motion sickness: 250-500 mg once for 1 hour before the expected start of the pitching or the appearance of the first symptoms of seasickness. The anti-foaming effect of Anvifen is enhanced by increasing the dose of the drug. At the onset of severe manifestations of seasickness (vomiting, etc.), administration of Anvifen is ineffective even in doses of 750-1000 mg.

Side effects:

Drowsiness, nausea. Enhancement of irritability, agitation, anxiety, dizziness, headache (at the first receptions), allergic reactions.

Overdose:

Symptoms: severe drowsiness, nausea, vomiting, fatty degeneration of the liver (taking more than 7 g), eosinophilia, lowering blood pressure, impaired renal function. Treatment: gastric lavage, intake activated charcoal and symptomatic therapy.

Interaction:

Extends and enhances the effect of hypnotics, narcotic analgesics, neuroleptics, antiparkinsonian and antiepileptic drugs.

Special instructions:

With prolonged use, it is necessary to periodically monitor the performance of the liver and peripheral blood. It is necessary to refrain from potentially dangerous activities requiring increased concentration of attention.

Effect on the ability to drive transp. cf. and fur:It is necessary to refrain from potentially dangerous activities requiring increased concentration of attention.

Form release / dosage:

Capsules 25 mg, 50 mg, 125 mg, 250 mg.

Packaging:

For 10 capsules of a single dosage in a contiguous cell package.

1, 2, 3 or 5 contour squares with instructions for use in a pack of cardboard.

Storage conditions:

In a dry, protected from light place at a temperature of no higher than 25 ° C.Keep out of the reach of children.

Shelf life:

3 years. Do not use after the expiration date printed on the package.

Terms of leave from pharmacies:On prescription

Registration number:LSR-006779/09

Date of registration:25.08.2009 / 18.08.2016

Expiration Date:Unlimited

The owner of the registration certificate:Anvilab, OOO Anvilab, OOO Russia

Manufacturer: & nbsp

FARMPROJECT, CJSC Russia

Representation: & nbspPharm Company Sotex CJSC Pharm Company Sotex CJSC Russia

Information update date: & nbsp04.09.2017

Illustrated instructions

Instructions

Anvifen® (Anvifen®)